中国·腾博-www.tengbo9885.com|官网首发

中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

2018
  • 0
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 
Nat Commun. 9(1):5361. (*: Corresponding authors, PMCID: PMC6299138)
Jia Q., Wu W., Wang Y., Alexander P.B., Sun C., Gong Z., Cheng J., Sun H., Guan Y., Xia X., Yang L., Yi X., Wan Y., Wang H., Futreal P.A., Li Q.-J.*, Zhu B.* (2018)


Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells.
Nature Medicine 24(10):1536-1544 (*: Corresponding authors, PMCID: PMC6211844)
Zhao L., He R., Long H., Guo B., Jia Q., Qin D., Liu S.-Q., Wang Z., Xiang T.,  Zhang J., Tan Y., Huang J., Chen J., Wang F., Xiao M., Gao J., Yang X., Zeng H., Wang X., Hu C., Alexander P. B., Symonds A.L.J.,  Yu J., Wan Y., Li Q.-J.*, Ye L.*, Zhu B.* (2018) 


03.23
2022
来源:
关键词:
相关阅读
关于腾博tengbo9885官网
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 腾博tengbo9885官网

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
XML 地图